Cerulean Pharma
Cerulean: Leadership in Nanoparticle-Drug Conjugates.
Launch date
Market cap
-
Enterprise valuation
€55—82m (Dealroom.co estimates Dec 2011.)
Cambridge Massachusetts (HQ)
Financials
Estimates*
EUR | 2015 |
---|---|
R&D budget | 24.0m |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
$12.1m | Series A | ||
$8.1m | Series B | ||
$10.0m | Series B | ||
$1.5m | Debt | ||
$24.0m | Series C | ||
$15.0m | Series D | ||
$13.0m | Growth Equity VC | ||
N/A | N/A | IPO | |
N/A | Acquisition | ||
Total Funding | €74.7m |